U.S. payers and CGP

TruSight Oncology Comprehensive (TSO Comprehensive) is the first U.S. FDA-approved, distributable comprehensive genomic profiling (CGP) kit with pan-cancer companion diagnostic (CDx) claims, across solid malignant neoplasms, conveys a distinct clinical utility that payers appreciate.

TSO Comprehensive is eligible for coverage for Medicare beneficiaries throughout the US under National Coverage Determination (NCD) 90.2¹. FDA-approved assays with companion diagnostic claims like TSO Comprehensive benefit from more than 30% increased covered beneficiary as compared to assays without CDx claims².

This webinar will highlight how your lab can navigate TSO Comprehensive reimbursement by engaging with your payers, which tools to use and information to highlight during the billing processes.  A regional laboratory serving a wide network across 7 states will share its experience navigating CGP RUO reimbursement, providing rapid access to CGP results for their oncologist through systematic lab-initiated testing and how TSO Comprehensive could positively impact their bottom line.

Learning objectives

• Learn about TSO Comprehensive unique value proposition for U.S. payers
• Equip your lab to engage with your payers to maximize reimbursement of your CGP
• Review a US regional lab experience in optimizing CGP reimbursement and implementing laboratory-initiated CGP testing to better serve its oncologists and patients

Speakers

John Fox, MD, MHA
Senior Medical Director, Market Access
Illumina

Brian D. Piening, PhD
Associate member, Cancer Immuno-Genomics Laboratory, Earle A. Chiles Research Institute, Providence Cancer Institute
Program Director, Providence Genomics

Pierre Del Moral, PhD, MBA
Director, Clinical Marketing and Market Development
Illumina

Cristyn Lauer, MBA
Principal Consultant
2C Ventures